Cellectis S.A. ADR Company Profile
NASDAQ: CLLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Cellectis S.A. at a glance
Cellectis S.A. ADR (NASDAQ: CLLS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Paris, France. Cellectis S.A. is led by Dr. Andre Choulika Ph.D. and employs about 224 people. The company's shares have traded publicly since 2015.
At a market capitalization of $125.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001627281, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Cellectis S.A. do?
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Business description based on the company's public filings.
Company information
- Legal name
- Cellectis S.A. ADR
- Ticker
- NASDAQ: CLLS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Andre Choulika Ph.D.
- Employees
- 224
- Headquarters
- 8, rue de la Croix Jarry, Paris, France
- Phone
- 33 1 81 69 16 00
- Website
- cellectis.com
- IPO year
- 2015
- Market cap
- $125.90M
- SEC CIK
- 0001627281
Companies similar to Cellectis S.A.
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRXPNRX Pharmaceuticals Inc. | 2.89 | -0.34% | $125.12M | vs CLLS |
| TNXPTonix Pharmaceuticals Holding Corp. | 7.28 | -3.58% | $124.86M | vs CLLS |
| HURATuHURA Biosciences Inc. | 1.93 | -2.53% | $122.99M | vs CLLS |
| SPRBSpruce Biosciences Inc. | 45.54 | +2.57% | $130.88M | vs CLLS |
| VTVTvTv Therapeutics Inc. Class A | 30.08 | -3.00% | $118.93M | vs CLLS |
| BGMBGM Group Ltd. Class A | 9.96 | +6.07% | $133.01M | vs CLLS |
| FHTXFoghorn Therapeutics Inc. | 1.99 | -4.78% | $118.18M | vs CLLS |
| COYACoya Therapeutics Inc. | 4.99 | +1.63% | $117.05M | vs CLLS |